Latest News

The European Huntington Association and the European Reference Network for Rare Neurological Diseases hosted a webinar on April 6th. The webinar, entitled, ‘Huntington’s Disease and COVID-19 pandemic – a difficult combination’ provided information about the specific risks for HD patients, an update on current HD studies and trials and some advice on how to cope with the new situation. Participants had the opportunity to participate in an extensive open Q and A session and. 14 speakers, including neuropsychologists, neurologists, neurogeneticists and psychiatrists were available to respond to questions and concerns in 18 languages.

Huntington’s Disease Youth Organization (HDYO) has announced the appointment of Hayley Hubberstey to the role of European chair on the board.

Last Friday, HCD’s office administrator Liz won the newly launched HCD Friday pub quiz, with 13 points out of a possible 20. Quizmaster and General Manager, Peter Brown, launched the pub night following a suggestion from one of our Real World Evidence team. The pub uses Microsoft Teams to link all HCD staff, all of whom are now working from home. The conversation flows easily, with much laughter and leg pulling and everyone on the team now looks forward to the virtual Friday gathering, all having a glass or can of their chosen beverage in front of them to toast colleagues.

The potential of gene therapy to transform treatment for patients with haemophilia is entering clinical practice. The literature in adeno-associated viral (AAV) vector-mediated gene therapy demonstrates improvement in endogenous factor levels over sustained periods, significant reduction in annualised bleed rates, lower exogenous factor usage and thus far a positive safety profile. Gene therapy is also associated improvements in the burden of illness for haemophilia patients as measured by HRQoL and economic analysis.

Rare Disease Day 2020 - raising awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. Rare Disease Day will be on February 29th 2020. As a research partner and advocate for the rare disease community, HCD Economics is sharing news of this event with our website community.

HCD’s Hayley Hubberstey, Real World Evidence Manager and Dr Harpal Dhillon, Global Medical Affairs Director attended ASH in December 2019 for the shared objective to learn the latest in terms of medical advances/understanding in HCD’s research areas of Sickle Cell Disease and Haemophilia and to identify 2020 research areas, that would benefit from the patient empowered methodology HCD has pioneered, alongside a need in the future research area to unearth evidence of burden of illness and provide expertise pro bono, in support of patient and political advocacy.

The International Gaucher Alliance (IGA) publishes a regular monthly newsletter. In the November 2019 edition reports are filed from all parts of the IGA organisation, including established and emerging National members of the Gaucher community such as Belgium, Albania, Pakistan and the United States.

Hayley Hubberstey, HCD Economics Real World Evidence (RWE) lead for research in Sickle Cell Disease, attended ASCAT last week (21st – 23rd October) and shares her selection of highlights from the conference in this report, and comments on how these inform and support the need for RWE research in SCD.

HCD Economics are looking to hire an experienced Project Coordinator for an immediate start to help grow the project management side of the business